NEPHROPLUS vs SUDEEPPHRM: Stock Comparison
SUDEEP PHARMA is the larger company by market capitalisation. NEPHROCARE HEALTH SERV L shows lower leverage, while SUDEEP PHARMA shows a lower P/E, a higher ROE and a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
NEPHROPLUS leads 2; SUDEEPPHRM leads 7 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Price
| Metric | NEPHROPLUS | SUDEEPPHRM |
|---|---|---|
| Live Price | ₹611.55 | ₹1,003.3 |
| Day Change | -0.46% | 0.26% |
| Volume | 1.53 L | 1.95 L |
| 52-Week High | ₹781.5 | ₹1,378 |
| 52-Week Low | ₹446 | ₹524.05 |
| Distance from 52W High | -21.75% | -27.19% |
Valuation
| Metric | NEPHROPLUS | SUDEEPPHRM |
|---|---|---|
| Market Cap | ₹6,124 Cr | ₹11,289 Cr |
| P/E Ratio | 79.5x | 61.74x |
| P/B Ratio | 5.47x | 12.78x |
| EPS | ₹3.19 | ₹3.59 |
| Book Value | ₹111.27 | ₹79.51 |
| Dividend Yield | 0% | 0.15% |
Growth
| Metric | NEPHROPLUS | SUDEEPPHRM |
|---|---|---|
| Revenue Growth (TTM YoY) | 0% | 0% |
| EPS Growth (TTM YoY) | 0% | 0% |
| Qtr Sales Growth | 0% | 0% |
| Qtr Profit Growth | 0% | 0% |
Profitability & Leverage
| Metric | NEPHROPLUS | SUDEEPPHRM |
|---|---|---|
| ROE | -0.83% | 19.41% |
| ROCE | 5.17% | 17.66% |
| Net Margin | 7.69% | 27.14% |
| Operating Margin | 7.3% | 36.7% |
| Debt to Equity | 0.01x | 0.17x |
Shareholding
As of Sep 2026 • change vs previous quarter| Metric | NEPHROPLUS | SUDEEPPHRM |
|---|---|---|
| Promoter Holding | 18.79%▼ 2.28 pp | 76.15% |
| FII Holding | 11.73%▲ 2.95 pp | 2.93%▲ 1.12 pp |
| DII Holding | 8.11%▼ 0.94 pp | 14.05%▼ 1.6 pp |
| Public Holding | 21.85%▲ 3.53 pp | 6.87%▲ 0.48 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: NEPHROCARE HEALTH SERV L and SUDEEP PHARMA.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.